Summary

Clinicians should consider the increase in total and cardiovascular disease-related mortality, weight gain, and risk of severe hypoglycemia prior to implementing an intensive glycemic therapy strategy according to findings from a substudy of the Action to Control Cardiovascular Risk in Diabetes [ACCORD; NCT00000620] trial.